local_hospital

The Rotterdam Eye Hospital

Address
lock Available on a paid plan

Eye Diseases

The Rotterdam Eye Hospital is active in ophthalmology research focused on a range of vision-threatening conditions. Current studies examine exudative age-related macular degeneration, neovascular age-related macular degeneration, geographic atrophy, central serous chorioretinopathy, and persistent corneal epithelial defect, with the goal of improving treatment effectiveness and patient outcomes.

  • Research includes testing new approaches for retinal disease, evaluating treatment combinations, and assessing therapies that may better preserve vision.
  • Studies also look at healing support for corneal surface disease and symptom control in chronic eye conditions.
  • The site supports clinical research aimed at both short-term improvement and longer-term disease management.

These trials reflect a strong focus on retina, macular, and corneal disorders, with an emphasis on finding safer and more effective care options.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Research at this site also covers inherited eye disease, especially conditions that affect vision from an early age or progress over time. Key studies involve retinitis pigmentosa and Stargardt disease, focusing on whether emerging therapies can slow disease progression and support retinal function.

  • Investigations are centered on inherited retinal disorders linked to genetic causes and long-term vision loss.
  • The research aims to evaluate whether new treatments can improve disease control and protect remaining sight.
  • These studies add an important genetic ophthalmology dimension to the hospital’s trial portfolio.

The work at Rotterdams Oogheelkundig Instituut highlights efforts to advance care for patients with rare, hereditary conditions where treatment options remain limited.

Specialized Vision and Ocular Surface Research

Several trials at the Rotterdam Eye Hospital focus on specific eye conditions such as acquired blepharoptosis and persistent corneal epithelial defect. These studies are designed to test new therapies that may improve eyelid function or support corneal healing more effectively than current care.

  • Research in this area includes evaluating treatments for drooping eyelids that can affect vision and daily comfort.
  • Ocular surface studies are examining ways to promote complete healing in hard-to-treat corneal defects.
  • The site’s work combines symptom relief, visual function, and tissue repair as key research goals.

Together, these studies show a broad commitment to improving both common and rare eye disorders through clinical investigation.

Site Overview

assignment
11
connected trials
corporate_fare
10
sponsors
science
16
IMPs

Activity Indicator

Last 6 months

2
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
11
Total trials linked
Highly Active
trending_upGrowing+100%
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 1 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
7
Sponsors (total)
10
Active sponsors
8

Sponsor Network

Top 8 by active trials.

lock +7 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 271 other sites in The Netherlands

description
Trial volume
11
Outperforms 70% of sites
public
Therapeutic diversity
2areas
Outperforms 34% of sites
groups
Sponsor diversity
10sponsors
Outperforms 72% of sites

Therapeutic Area Benchmark — The Netherlands

Select a therapeutic area to compare against other sites in The Netherlands.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: The Netherlands

Market Share

Country: The Netherlands

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in The Rotterdam Eye Hospital

lock Showing 1 of 11 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 16 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Adeno-Associated Virus Serotype 2 Encoding Soluble Cd592Unknown2023-08-112025-02-27

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.